WE ARE
A preclinical with a novel breakthrough therapeutic for treating cancer and fibrosis. Our world leading IP covers a global footprint
of over 5 billion people, 11 different cancers with a potential market share worth more than $103 billion annually, and now includes broad areas for fibrotic treatment.
WE HELP
Unmet medical needs in many cancers and fibroid diseases with our novel small molecule TGFB SMAD3 singling inhibitor therapeutics.
WE ARE ON THE MOVE
In active IND, with a new AI partnership that innovates product development and lead optimisation at a greater speeds and lower costs. Our first-in-human clinical trials are organised in partnership with a world leading multibillion CRO and queued for launch.
OUR VALUE PROPOSITION
We are the only known small molecule in advanced development as a TGFB SMAD3 inhibitor therapeutic in a sector where Pharma has committed over $59 billion to discover new TGFB products, including $11.5 billion to acquire an upstream large molecule TGFB SMAD3 inhibitor for fibrotic for use. Our downstream small molecule solution shows broader promise with a potentially larger market in successfully treating both cancer and fibrosis.
TGF-β cytokines regulate cell fate decisions during development, tissue homeostasis and regeneration, and are major players in tumorigenesis, fibrotic disorders, immune malfunctions and various congenital diseases.
Effects of the TGF-β family are mediated by a combinatorial set of ligands and receptors and by a common set of receptor-activated mothers against decapentaplegic homologue (Smad) transcription factors.
Suppression of NK cell-mediated immuno surveillance via the Smad3-E4BP4 axis contributes to tumor development, cancer progression and fibrosis. Disruption of Smad3 is shown to reverse these effects.
Moexa’s TGF-β SMAD3 therapeutic has secured world leading IP status and is identified as a novel first-in-class solution with potential to bring new drugs therapies for both cancer and fibrosis.
MOEXA’S OWNS SMALL MOLECULE TGFB – SMAD3 INHIBITOR TECHNOLOGY that has been proven in animal studies to effectively kill cancer cells with minimal toxicity indications. The therapy has been shown to also treat fibrosis and is secured by world leading IP for both cancer and fibrosis in all major markets. The company is completing IND to prepare for first-in-human clinical trials.
-
US Patent Establishes Global IP Leadership
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test.
February 6, 2024 -
New Board European Patents
Bring to the table win-win survival strategies to ensure proactive domination.
June 15, 2021 -
New Anti-Fibrotic & Collaboration Agreement
At the end of the day, going forward, a new normal that has evolved from generation.
December 15, 2020 -
Successful Study POC Completion
User generated content in real-time will have multiple touchpoints for offshoring.
August 17, 2020